270 results match your criteria Waldenstrom Hypergammaglobulinemia


Familial Waldenström Macroglobulinemia: Families Informing Populations.

Authors:
Mary L McMaster

Hematol Oncol Clin North Am 2018 10 26;32(5):787-809. Epub 2018 Jul 26.

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, 9609 Medical Center Drive, Room 6E516, MSC 9772, Bethesda, MD 20892-9772, USA; Commissioned Corps of the US Public Health Service, US Department of Health and Human Services, 330 C Street SW, Washington, DC 20416, USA. Electronic address:

Familial clustering of Waldenström macroglobulinemia (WM) has been observed for nearly 6 decades. Family studies have provided seminal observations in delineating the phenotypic spectrum of WM susceptibility and confirming the importance of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (IgM MGUS) as a precursor condition for WM, providing the rationale for large population-based epidemiologic studies of IgM MGUS and WM, and providing both the basis and the material for ongoing genetic studies aimed at identifying WM predisposition genes. Together, these investigations may help elucidate the host factors underlying WM development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2018.05.006DOI Listing
October 2018
3 Reads

Waldenström macroglobulinemia treatment algorithm 2018.

Authors:
Morie A Gertz

Blood Cancer J 2018 05 1;8(4):40. Epub 2018 May 1.

Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA.

Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0076-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928091PMC
May 2018
4 Reads

Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.

Ann Hematol 2018 Mar 20;97(3):475-484. Epub 2018 Jan 20.

Hematology Department, University Hospital of Salamanca and Research Biomedical Institute of Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007, Salamanca, Spain.

Immunoglobulin M (IgM) monoclonal gammopathies show considerable variability, involving three different stages of presentation: IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), asymptomatic Waldenström's macroglobulinemia (AWM), and symptomatic WM (SWM). Despite recent findings about the genomic and transcriptomic characteristics of such disorders, we know little about the causes of this clinical heterogeneity or the mechanisms involved in the progression from indolent to symptomatic forms. To clarify these matters, we have performed a gene expression and mutational study in a well-characterized cohort of 69 patients, distinguishing between the three disease presentations in an attempt to establish the relationship with the clinical and biological features of the patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-3207-3DOI Listing
March 2018
70 Reads

Characteristics and Prognosis of Patients with Immunoglobulin M Monoclonal Gammopathy.

J Clin Exp Hematop 2017 ;57(2):47-53

Department of Transfusion Medicine, Asahi General Hospital.

Many patients with immunoglobulin M (IgM) monoclonal gammopathy remain asymptomatic and, consequently, untreated; however, few studies have evaluated the clinical course and prognosis of these patients. Using the screening procedures at our hospital, 74 patients with IgM monoclonal gammopathy were selected. We excluded 11 patients in whom the treatment for lymphoid neoplasms had been initiated at the time of IgM monoclonal protein detection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3960/jslrt.17025DOI Listing
February 2018
13 Reads

Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.

Haematologica 2017 12 5;102(12):2077-2085. Epub 2017 Oct 5.

Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

We analyzed and CXCR4 mutation status of 260 patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance using allele-specific real time quantitative polymerase chain reaction and Sanger sequencing, respectively. A subgroup of 119 patients was further studied with next-generation sequencing of 11 target genes (, , , , , , , , , , and ). (L265P) was found at diagnosis in 91% of patients with Waldenström macroglobulinemia and in 60% of patients with IgM monoclonal gammopathy of undetermined significance using allele-specific polymerase chain reaction analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.172718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709107PMC
December 2017
25 Reads

Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Mayo Clin Proc 2017 05;92(5):838-850

Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address:

Monoclonal gammopathies comprise a spectrum of clonal plasma cell disorders that include monoclonal gammopathy of undetermined significance, multiple myeloma, and Waldenström macroglobulinemia. In this review, we outline the epidemiology, etiology, classification, diagnosis, and treatment of monoclonal gammopathy-associated peripheral neuropathy. Monoclonal gammopathy of undetermined significance is relatively common in the general population, with a prevalence of 3% to 4% among individuals older than age 50 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2017.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573223PMC
May 2017
40 Reads

Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.

Ann Hematol 2017 Jun 9;96(6):971-976. Epub 2017 Mar 9.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.

A broad spectrum of diseases are associated with IgM monoclonal gammopathy, including Waldenstrom macroglobulinemia (WM), various types of B cell non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), primary amyloidosis (AL), and monoclonal gammopathy of undetermined significance (MGUS); these are called IgM monoclonal gammopathy related diseases (IgM-RD). We investigated MYD88 L265P and WHIM-like CXCR4 mutations in various IgM-RD. Patients with serum immunofixation electrophoresis confirmed IgM monoclonal gammopathy who had enough material for DNA extraction and presented between January 2008 and October 2016 at Peking Union Medical College Hospital were enrolled in this cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-017-2968-zDOI Listing
June 2017
22 Reads

Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.

Best Pract Res Clin Haematol 2016 06 4;29(2):187-193. Epub 2016 Sep 4.

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, United States.

Since the initial identification of patients with monoclonal elevation of gamma globulin and associated clinical symptoms in 1944 by Jan Waldenström, several new insights have been gained using a range of approaches. For example, IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia are defined clinical precursor states to symptomatic Waldenström's macroglobulinemia. Epidemiologic studies have established the prevalence of these conditions and the estimated risk of progression to symptomatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.08.015DOI Listing
June 2016
16 Reads

Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.

Br J Haematol 2017 12 8;179(5):849-851. Epub 2016 Sep 8.

Amyloidosis and Myeloma Unit, Department of Haematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14266DOI Listing
December 2017
9 Reads

[Acquired von Willebrand syndrome in three patients and literature review].

Zhonghua Xue Ye Xue Za Zhi 2016 Aug;37(8):692-5

Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, China.

Objective: To deepen the understanding of acquired von Willebrand syndrome (AVWS).

Methods: The clinical data of 3 patients were analyzed and related literature were reviewed.

Results: ① Case 1, a 70- year- old male, diagnosed as Waldenstrom macroglobulinemia and AVWS, was presented with spontaneous epitaxis and bruising. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.08.012DOI Listing
August 2016
5 Reads

Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.

Leuk Lymphoma 2017 04 22;58(4):773-780. Epub 2016 Aug 22.

b Division of Hematology , Mayo Clinic , Rochester , MN , USA.

In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenström macroglobulinemia (WM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1217527DOI Listing
April 2017
14 Reads

The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.

Leuk Res 2016 07 4;46:85-8. Epub 2016 May 4.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address:

Objectives: We retrospectively evaluated the clinical features, serum levels of IgM, and prevalence of IgM related diseases in patients with serum immunofixation electrophoresis (sIFE) confirmed IgM monoclonal gammopathy at our center.

Methods: We included patients with sIFE confirmed IgM monoclonal gammopathy between January 2008 and December 2014 in this retrospective study. We evaluated clinical data, sIFE, serum IgM levels, and diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.05.002DOI Listing
July 2016
27 Reads

[Relapsing vascular purpura and Sjögren syndrome: what is the link?].

Pan Afr Med J 2015 1;22:92. Epub 2015 Oct 1.

Service de Médecine Interne, Hôpital Razi, La Manouba 2010, Faculté de médecine de Tunis, Tunisie.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11604/pamj.2015.22.92.7830DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732652PMC
September 2016
14 Reads

Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid.

Int J Lab Hematol 2016 Apr 21;38(2):133-40. Epub 2016 Jan 21.

NeoGenomics Laboratories, Irvine, CA, USA.

Introduction: Detection of mutations in the myeloid differentiation primary response gene 88 (MYD88) has clinical implications on diagnosis and therapy, especially in patients with Waldenström's macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (IgM-MGUS). We describe a method that provides greatly increased sensitivity for detecting minority mutations in MYD88.

Methods: We used a locked nucleic acid oligonucleotide to block amplification of wild-type DNA during polymerase chain reaction (PCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.12456DOI Listing
April 2016
22 Reads

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

Br J Haematol 2016 Mar 13;172(5):735-44. Epub 2015 Dec 13.

Bing Center for Waldenström's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA.

CXCR4(WHIM) somatic mutations are distinctive to Waldenström Macroglobulinaemia (WM), and impact disease presentation and treatment outcome. The clonal architecture of CXCR4(WHIM) mutations remains to be delineated. We developed highly sensitive allele-specific polymerase chain reaction (AS-PCR) assays for detecting the most common CXCR4(WHIM) mutations (CXCR4(S338X C>A and C>G) ) in WM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13897DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409813PMC
March 2016
65 Reads

Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.

PLoS One 2015 9;10(9):e0136505. Epub 2015 Sep 9.

Hospices Civils de Lyon, Pierre Bénite, France; INSERM 1052, CNRS 5286, CRCL, Lyon, France; University of Lyon, Lyon, France; ProfilExpert, Lyon, France.

The MYD88 L265P is a recurrent somatic mutation in neoplastic cells from patients with Waldenström Macroglobulinemia (WM). We identified the MYD88 L265P mutation in three individuals from unrelated families, but its presence did not explain the disease segregation within these WM pedigrees. We observed the mutation in these three individuals at high allele fractions in DNA extracted from EBV-immortalized Lymphoblastoid cell lines established from peripheral blood (LCL), but at much lower allele fractions in DNA extracted directly from peripheral blood, suggesting that this mutation is present in a clonal cell subpopulation rather than of germ-line origin. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136505PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564105PMC
May 2016
72 Reads

Macro-quest.

Blood 2015 Apr;125(15):2318-9

MAYO CLINIC.

In this issue of Blood, Paiva et al provide important information on the cell of origin in Waldenström macroglobulinemia (WM), a longstanding puzzle due to conflicting and incomplete data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-02-628404DOI Listing
April 2015
7 Reads

Bevacizumab therapy and multimodal ultrawide-field imaging in immunogammopathy maculopathy secondary to Waldenström's macroglobulinemia.

Ophthalmic Surg Lasers Imaging Retina 2015 Feb;46(2):262-5

Waldenström's macroglobulinemia (WM) is associated with retinal findings of hyperviscosity, such as venous dilation, and findings of immunogammopathy maculopathy, such as serous macular detachment. This report describes a case of bilateral serous macular detachment with intraretinal schisis-like fluid in a patient with WM. Enhanced depth imaging optical coherence tomography revealed a thickened choroid with hyperreflective accumulations in the retinal pigment epithelium layer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3928/23258160-20150213-06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455023PMC
February 2015
9 Reads

CD4⁺ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemia.

Int J Cancer 2015 Sep 26;137(5):1076-84. Epub 2015 Feb 26.

José Carreras Center for Immuno and Gene Therapy, Department of Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.

Hyperphosphorylated paratarg-7 (pP-7) carrier state is the strongest and most frequent molecular risk factor for MGUS, multiple myeloma (MM) and Waldenström's macroglobulinemia (WM), inherited autosomal-dominantly and, depending on the ethnic background, found in up to one third of patients with MGUS/MM. Since P-7 is the antigenic target of paraproteins that do not distinguish between wtP-7 and pP-7, we investigated CD4(+) T-cell responses in pP-7(+) patients and controls. Peptides spanning amino acids 1-35 or 4-31 containing phosphorylated or nonphosphorylated serine17 were used for stimulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29478DOI Listing
September 2015
10 Reads

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

Blood 2015 Apr 5;125(15):2370-80. Epub 2015 Feb 5.

Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain;

Although information about the molecular pathogenesis of Waldenström macroglobulinemia (WM) has significantly advanced, the precise cell of origin and the mechanisms behind WM transformation from immunoglobulin-M (IgM) monoclonal gammopathy of undetermined significance (MGUS) remain undetermined. Here, we undertook an integrative phenotypic, molecular, and genomic approach to study clonal B cells from newly diagnosed patients with IgM MGUS (n = 22), smoldering (n = 16), and symptomatic WM (n = 11). Through principal component analysis of multidimensional flow cytometry data, we demonstrated highly overlapping phenotypic profiles for clonal B cells from IgM MGUS, smoldering, and symptomatic WM patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-09-602565DOI Listing
April 2015
88 Reads

[Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation].

Rev Med Interne 2015 Jul 5;36(7):444-9. Epub 2014 Nov 5.

Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M.-Polonovski, 59037 Lille, France. Electronic address:

Introduction: Monoclonal gammopathy of undetermined significance (MGUS) is a frequent entity in the general population. The incidence rate of fortuitous discovery of a monoclonal component in asymptomatic patients is increasing nowadays. The majority of MGUS is being addressed to a hematologist for diagnosis or follow-up by their generalist practitioners. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revmed.2014.10.366DOI Listing
July 2015
7 Reads

Immunostaining of skin biopsy adds no diagnostic value in MGUS-associated peripheral neuropathy.

J Neurol Sci 2015 Feb 26;349(1-2):60-4. Epub 2014 Dec 26.

Department of Neurology, Odense University Hospital, Odense, Denmark.

Background And Purpose: For several decades an association between MGUS, IgM-MGUS in particular, and peripheral neuropathy has been suspected. Several histopathology studies have shown binding of IgM to myelin and a secondary widening of myelin lamellae in cutaneous nerves and in the sural nerve of patients with IgM-MGUS, or Waldenström's Macroglobulinaemia (WM), and peripheral neuropathy. In this retrospective study we investigated the value of skin biopsy examination in the diagnosis of MGUS- and WM-associated peripheral neuropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2014.12.026DOI Listing
February 2015
11 Reads

Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.

Clin Lymphoma Myeloma Leuk 2015 Mar 28;15(3):177-186.e4. Epub 2014 Sep 28.

Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.

Background: Clinical guidelines have recommended annual follow-up examinations of most patients with monoclonal gammopathy of undetermined significance (MGUS); however, evidence supporting this practice is lacking. We performed a population-based study to examine the patterns of disease presentation and outcomes of patients with multiple myeloma, Waldenström macroglobulinemia, and lymphoplasmacytic lymphoma (monoclonal gammopathy-associated malignancies) comparing those with or without a previous MGUS follow-up examination.

Materials And Methods: Patients with monoclonal gammopathy-associated malignancy from 1994 through 2007 were identified using the Surveillance, Epidemiology, and End Results-Medicare linked database and divided into 2 cohorts: those with follow-up (MGUS follow-up examination preceding the diagnosis) and those with no follow-up (no such follow-up examination). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650140041
Publisher Site
http://dx.doi.org/10.1016/j.clml.2014.09.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344843PMC
March 2015
17 Reads

Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.

Int J Hematol 2015 Feb 28;101(2):133-9. Epub 2014 Nov 28.

Department of Hematology, Rheumatology & Infectious Diseases, Kumamoto University of Medicine, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Amyloid light-chain amyloidosis (ALA) is a rare disease with poor prognosis and is often associated with monoclonal gammopathy of undetermined significance, multiple myeloma, or Waldenström macroglobulinemia. Only high-dose melphalan with auto-peripheral blood stem cell transplantation (PBSCT) has shown high long-term hematological response rates, but combinations with novel agents, including bortezomib or lenalidomide, have recently shown high hematological response rates for AL amyloidosis patients. In the present study, we treated eight Japanese patients with AL amyloidosis using bortezomib, cyclophosphamide, and dexamethasone (CyBorD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-014-1705-9DOI Listing
February 2015
29 Reads

Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia.

Am J Hematol 2015 Mar 16;90(3):E51-2. Epub 2015 Jan 16.

Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23910DOI Listing
March 2015
26 Reads

[Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].

Vnitr Lek 2014 Oct;60(10):861-79

Presence of monoclonal immunoglobulin in serum or urine is a relatively common event affecting about 3.2 % of people over 50. Isolated increase of only one type of free light chain, either κ or λ, is detected in 0. Read More

View Article

Download full-text PDF

Source
October 2014
35 Reads

Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction.

Appl Immunohistochem Mol Morphol 2014 Nov-Dec;22(10):768-73

*Department of Hematology, University Hospital of Salamanca †Center of Investigation in Cancer (CIC), Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain.

MYD88 L265P mutation has been reported in ∼90% of Waldenström's Macroglobulinemia (WM) patients and immunoglobulin M (IgM) monoclonal gammopathies of uncertain significance (MGUS), as well as in some cases of lymphoma and chronic lymphocytic leukemia. The present study aimed to develop a real-time allele-specific oligonucleotide PCR (ASO-RQ-PCR) to detect the MYD88 L265P mutation. We first evaluated the reproducibility and sensitivity of the technique with a diluting experiment of a previously known positive sample. Read More

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/appliedimmunohist/2014/11000/De
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAI.0000000000000020DOI Listing
July 2015
104 Reads

[Skin disorders associated with monoclonal gammopathies].

Ned Tijdschr Geneeskd 2014 ;158:A6717

Leids Universitair Medisch Centrum, Leiden.

A monoclonal gammopathy is a condition in which a monoclonal immunoglobulin (M-protein, formerly known as paraprotein) produced by a clonal proliferation of plasma cells is present in the blood. The spectrum of monoclonal gammopathies includes monoclonal gammopathy of uncertain significance (MGUS), multiple myeloma, Waldenström disease, plasmacytoma and primary amyloidosis. Various skin diseases are associated with monoclonal gammopathies. Read More

View Article

Download full-text PDF

Source
December 2014
7 Reads

Inactivation of protein-phosphatase 2A causing hyperphosphorylation of autoantigenic paraprotein targets in MGUS/MM is due to an exchange of its regulatory subunits.

Int J Cancer 2014 Nov 5;135(9):2046-53. Epub 2014 Apr 5.

José-Carreras-Center for Immuno- and Gene Therapy, Internal Medicine I, Saarland University Medical School, Homburg (Saar), Germany.

Hyperphosphorylated paratarg-7 (pP-7) carrier state is the strongest molecularly defined risk factor for monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM). pP-7 is inherited as autosomal-dominant trait and depending on the ethnic background is found in over one-third of MGUS/MM patients. P-7, which is the antigenic paraprotein target in these patients, is hyperphosphorylated at serine17. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28864DOI Listing
November 2014
20 Reads

Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Leukemia 2014 Aug 10;28(8):1698-704. Epub 2014 Feb 10.

1] Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Medicine, Harvard Medical School, Boston, MA, USA.

MYD88 L265P is highly prevalent in Waldenstrom's Macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (MGUS). We investigated whether MYD88 L265P could be identified by peripheral blood (PB) allele-specific PCR. MYD88 L265P was detected in untreated WM (114/118; 96. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/leu.2014.65DOI Listing
August 2014
13 Reads

What is Waldenström macroglobulinemia?

Authors:
Morie A Gertz

Leuk Lymphoma 2013 Nov 29;54(11):2345-6. Epub 2013 Jul 29.

Department of Medicine, Mayo Clinic , Rochester, MN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.813506DOI Listing
November 2013
14 Reads

[Acquired von Willebrand syndrome: a case series of nine patients and literature review].

Rev Med Interne 2014 Mar 7;35(3):154-9. Epub 2013 Jun 7.

Service de médecine interne, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France; Faculté de médecine, université Paris Descartes, Paris Sorbonne Cité, 75005 Paris, France. Electronic address:

Purpose: Whereas von Willebrand disease is the most common constitutional bleeding disorder, acquired von Willebrand syndrome is rare.

Methods: Retrospective, monocentric descriptive study of consecutive cases of acquired von Willebrand syndrome diagnosed between 2000 and 2012. Diagnostic criteria included: absence of a past history of mucocutaneous bleeding, with low plasma levels of factor VIII (FVIII) and von Willebrand factor (VWF), ristocetine cofactor activity (RCo) and antigen (Ag). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02488663130008
Publisher Site
http://dx.doi.org/10.1016/j.revmed.2013.02.039DOI Listing
March 2014
7 Reads

Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Leukemia 2014 Jan 22;28(1):166-73. Epub 2013 Apr 22.

1] Hospital Universitario de Salamanca, Department of Hematology, Salamanca, Spain [2] IBSAL IBMCC (USAL-CSIC), Salamanca, Spain.

Although multiparameter flow cytometry (MFC) has demonstrated clinical relevance in monoclonal gammopathy of undetermined significance (MGUS)/myeloma, immunophenotypic studies on the full spectrum of Waldenström's Macroglobulinemia (WM) remain scanty. Herein, a comprehensive MFC analysis on bone marrow samples from 244 newly diagnosed patients with an immunoglobulin M (IgM) monoclonal protein was performed, including 67 IgM-MGUS, 77 smoldering and 100 symptomatic WM. Our results show a progressive increase on the number and light-chain-isotype-positive B-cells from IgM-MGUS to smoldering and symptomatic WM (P<. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/leu.2013.124DOI Listing
January 2014
18 Reads

Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.

Rev Invest Clin 2012 Nov-Dec;64(6 Pt 2):604-8

Centro de Hematología y Medicina Interna de Puebla.

Material And Methods: In a 30-year period in a single institution, 23 cases of systemic immunoglobulin light chain amyloidosis (AL) were identified, within a group of 1,388 individuals with some form of a hematological malignancy.

Results: AL is 14 times less frequent in Mexico than in Caucasians and it represents 15% of all monoclonal gammopathies. Median age was 57 years (range 39-98); there were 11 males and 12 females. Read More

View Article

Download full-text PDF

Source
June 2013
10 Reads

Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.

Arch Pathol Lab Med 2013 Apr;137(4):580-5

Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53792-2472, USA.

Lymphoplasmacytic lymphoma (LPL) is a low-grade, B-cell neoplasm composed of small lymphocytes, plasmacytoid lymphocytes, and plasma cells that typically involve the bone marrow, and it is associated with an immunoglobulin M (IgM) gammopathy. The definition of Waldenström macroglobulinemia (WM) and its relationship to LPL has been confusing in the past. In addition, the diagnosis of LPL itself can be challenging because LPL lacks disease-specific morphologic, immunophenotypic, and genetic features to differentiate it from other mature B-cell neoplasms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2012-0034-RSDOI Listing
April 2013
15 Reads

Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.

Clin Lymphoma Myeloma Leuk 2013 Apr 13;13(2):187-90. Epub 2013 Mar 13.

Department of Medicine, Division of Hematology, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.

Monoclonal gammopathy of undetermined significance (MGUS) of IgM type is the strongest risk factor for the development of Waldenström macroglobulinemia (WM). The clinical management of WM has changed considerably over recent years, which is reflected in the use of new therapeutic agents (eg, purine analogues, monoclonal antibodies, and thalidomide- and bortezomib-based therapies), risk-and-response-adjusted stratification of treatments, and improvement in supportive care measures. However, because of the rarity of WM, there are few phase III randomized clinical studies to guide therapy and evaluate overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.02.010DOI Listing
April 2013
4 Reads

Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.

Clin Lymphoma Myeloma Leuk 2013 Apr 13;13(2):184-6. Epub 2013 Mar 13.

Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Monoclonal gammopathy of undetermined significance of the immunoglobulin M class was diagnosed in 213 patients at the Mayo Clinic, 29 (14%) of whom developed lymphoma, Waldenström macroglobulinemia, or a related disorder over 1567 person-years of follow-up. The cumulative probability of progression was 10% at 5 years, 18% at 10 years, and 24% at 15 years, or approximately 1.5% per year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.02.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654087PMC
April 2013
14 Reads

Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Clin Lymphoma Myeloma Leuk 2013 Apr 9;13(2):208-10. Epub 2013 Mar 9.

Department of Hematology, Niguarda Ca' Granda Hospital, Milan, Italy.

Waldenström macroglobulinemia (WM) (symptomatic and indolent) and immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (IgMMGUS) can be identified based on the bone marrow (BM) infiltration and the existence of symptoms. The purpose of this study was to investigate the biological and genetic characteristics of both disorders comparing the molecular signature of WM versus IgMMGUS using microarray analysis. We investigated BM CD19(+) cells isolated from 21 WM patients and 10 IgMMGUS cases, and CD138(+) BM cells isolated from all of the WM patients and 4 of the IgMMGUS cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.02.012DOI Listing
April 2013
9 Reads

Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia.

Neth J Med 2013 Mar;71(2):54-62

St. Antonius Hospital Nieuwegein, The Netherlands.

On behalf of the lymphoma and multiple myeloma working parties of the Dutch/Belgian Haemato-Oncology Foundation for Adults in The Netherlands (HOVON), we present a guideline for diagnosis and management of Waldenström's macroglobulinemia (WM). Considering the indolent behaviour and heterogeneous clinical presentation of WM, it is crucial to determine the right indications for treatment, as well as to individualise therapeutic options. There are significant differences from the approach to multiple myeloma or the treatment of other indolent non-Hodkgin lymphomas, and these results cannot always be extrapolated. Read More

View Article

Download full-text PDF

Source
March 2013
5 Reads

Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.

Leuk Lymphoma 2013 Nov 17;54(11):2485-9. Epub 2013 Apr 17.

Department of Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo , Pavia , Italy.

We characterized immunoglobulin heavy chain (IGH) gene rearrangements and searched for clusters of stereotyped B-cell receptors in 123 patients with Waldenström macroglobulinemia (WM; n = 59) or immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MGUS) (n = 64). A productive monoclonal IGHV-D-J rearrangement was obtained in 99/123 patients (80%). Immunoglobulin heavy chain variable (IGHV) genes were mutated in 94/99 patients (95%) with a median somatic hypermutation rate of 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.779689DOI Listing
November 2013
15 Reads

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

Blood 2013 Mar 25;121(13):2522-8. Epub 2013 Jan 25.

Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.

A study has shown that MYD88 (L265P) is a recurring somatic mutation in Waldenström's macroglobulinemia (WM). We developed an allele-specific polymerase chain reaction (PCR) for this mutation, and analyzed bone marrow or peripheral blood samples from 58 patients with WM, 77 with IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), 84 with splenic marginal zone lymphoma (SMZL), and 52 with B-cell chronic lymphoproliferative disorders (B-CLPD). MYD88 (L265P) was detected in 58/58 (100%) patients with WM, 36/77 (47%) with IgM-MGUS, 5/84 (6%) with SMZL, and 3/52 (4%) with B-CLPD. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/content/121/13/2522.full.pdf
Web Search
http://www.bloodjournal.org/content/early/2013/01/25/blood-2
Web Search
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-09-45
Publisher Site
http://dx.doi.org/10.1182/blood-2012-09-457101DOI Listing
March 2013
32 Reads

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Blood 2013 Mar 15;121(11):2051-8. Epub 2013 Jan 15.

Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in >90% of Waldenström macroglobulinemia (WM) patients. MYD88 L265P was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients. We therefore developed conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays for more sensitive detection and quantification of MYD88 L265P. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-09-454355DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596964PMC
March 2013
28 Reads

Hypergammaglobulinemic purpura of Waldenström.

Dermatol Online J 2012 Dec 15;18(12). Epub 2012 Dec 15.

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, USA.

We report a case of a 33-year-old-woman with a one-year history of bilateral lower extremity vasculitis and laboratory evidence of hypergammaglobulinemia with otherwise unremarkable routine laboratory and rheumatologic studies. Her clinical picture, together with histopathologic evidence of leukocytoclastic vasculitis, favor a diagnosis of hypergammaglobulinemic purpura of Waldenström. Read More

View Article

Download full-text PDF

Source
December 2012
23 Reads

Differential diagnosis of monoclonal gammopathy of undetermined significance.

Hematology Am Soc Hematol Educ Program 2012 ;2012:595-603

Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.

Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic plasma cell disorder occurring in 4.2% of adults > 50 years of age, which can progress into symptomatic diseases either through proliferation of the plasma cell clone, giving rise to multiple myeloma and other lymphoplasmacellular neoplasms, or through organ damage caused by the monoclonal protein, as seen in light-chain amyloidosis and related conditions. Differential diagnosis of asymptomatic and symptomatic monoclonal gammopathies is the determinant for starting therapy. Read More

View Article

Download full-text PDF

Source
http://asheducationbook.hematologylibrary.org/content/2012/1
Web Search
http://dx.doi.org/10.1182/asheducation-2012.1.595DOI Listing
June 2013
2 Reads

CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma.

Am J Clin Pathol 2012 Dec;138(6):867-76

Dept of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

The majority of plasma cell myelomas (PCMs) are positive for CD200, a membrane protein with immunosuppressive function. There are no flow cytometry data in the literature on plasma cell CD200 expression in other immunoproliferative disorders. Therefore we used flow cytometry to study the expression of CD200 on plasma cells in diagnostic bone marrow aspirates from 61 patients with monoclonal gammopathy of undetermined significance (MGUS) and 10 patients with lymphoplasmacytic lymphoma (LPL). Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ajcp/article-lookup/doi/10.1309/AJC
Publisher Site
http://dx.doi.org/10.1309/AJCP3TQR1TFHHGASDOI Listing
December 2012
11 Reads

Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study.

Haematologica 2012 Jun 16;97(6):854-8. Epub 2011 Dec 16.

Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.

No comprehensive evaluation has been made to assess the risk of viral and bacterial infections among patients with monoclonal gammopathy of undetermined significance. Using population-based data from Sweden, we estimated risk of infections among 5,326 monoclonal gammopathy of undetermined significance patients compared to 20,161 matched controls. Patients with monoclonal gammopathy of undetermined significance had a 2-fold increased risk (P<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2011.054015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366650PMC
June 2012
6 Reads

Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Oncology (Williston Park) 2011 Jun;25(7):578-86

Monoclonal gammopathy of undetermined significance (MGUS) is defined as a serum M protein level of less than 3 g/dL, less than 10% clonal plasma cells in the bone marrow, and the absence of end-organ damage. The prevalence of MGUS is 3.2% in the white population but is approximately twice that high in the black population. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923465PMC
June 2011
8 Reads

Emerging concepts in monoclonal gammopathy of undetermined significance.

Authors:
César O Freytes

Bol Asoc Med P R 2010 Oct-Dec;102(4):43-6

Hematopoietic Stem Cell Transplant Program, Audie L. Murphy Memorial Veterans Hospital, 7400 Merton Minter Blvd, San Antonio, TX, USA.

Monoclonal gammopathy of undetermined significance (MGUS) is frequently diagnosed in the elderly population. Most physicians will have to evaluate and manage patients with this condition. Recent studies have clarified risk factors, natural history, prognosis and complications of this common condition. Read More

View Article

Download full-text PDF

Source
August 2011
5 Reads

Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.

Clin Vaccine Immunol 2011 Jun 20;18(6):969-77. Epub 2011 Apr 20.

Department of Infectious Diseases, NU Hospital Organization, Trollhättan/Uddevalla, Sweden.

Whereas patients with multiple myeloma (MM) have a well-documented susceptibility to infections, this has been less studied in other B-cell disorders, such as Waldenstrom's macroglobulinemia (WM) and monoclonal gammopathy of undetermined significance (MGUS). We investigated the humoral immunity to 24 different pathogens in elderly patients with MM (n = 25), WM (n = 16), and MGUS (n = 18) and in age-matched controls (n = 20). Antibody titers against pneumococci, staphylococcal alpha-toxin, tetanus and diphtheria toxoids, and varicella, mumps, and rubella viruses were most depressed in MM patients, next to lowest in WM and MGUS patients, and highest in the controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/CVI.00021-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122605PMC
June 2011
12 Reads